Quantapore Inc. is a biotechnology company focused on the development and commercialization of an ultra low-cost, high-throughput DNA sequencing platform. Based in Menlo Park, CA, the company was founded in 2009 and is well on its way to the commercialization of its novel sequencing platform.
The combination of low cost, long reads, simple workflow and fast sample to result turnaround time holds the promise to make Quantapore Inc. one of the world’s leading sequencing system providers.
Quantapore Inc. closed a Series C financing round in September 2016, led by China BioPharma Capital I, a venture capital fund advised by TVM Capital Life Science via its Hong Kong based office. Details of the financing were not disclosed.